Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy
Novo Nordisk slipped 1.5% to 237.90 Danish crowns in Copenhagen on Thursday, despite the FDA signing off on a higher-dose Wegovy injection. The stock remained in the red after Eli Lilly unveiled new obesity drug results, and as Reuters flagged that semaglutide patent expiry in India could clear the way for lower-cost generics of the compound found in both Wegovy and Ozempic. That’s become a real concern now, with Novo still scrambling to reassure investors after a rough February. On Feb. 4, the company projected that both 2026 sales and operating profit could slide by up to 13%. Later in the month, on Feb. 23, Reuters reported Novo shares tumbled more than 16% after CagriSema—its next-gen obesity hopeful—fell short against Lilly’s competing drug in a direct trial.
